Boston Scientific (BSX) ended the recent trading session at $42.73, demonstrating a +1.64% change from the preceding day’s closing price. The stock’s performance was ahead of the S&P 500’s daily gain of 0.6%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.64%.
Heading into today, shares of the medical device manufacturer had lost 2.46% over the past month, lagging the Medical sector’s loss of 1.97% and the S&P 500’s gain of 1.34%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company’s earnings report is set to be unveiled on October 28, 2026. The company is predicted to post an EPS of $0.76, indicating a 1.33% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $5.17 billion, indicating a 2.12% increase compared to the same quarter of the previous year.
BSX’s full-year Zacks Consensus Estimates are calling for earnings of $3.25 per share and revenue of $21.17 billion. These results would represent year-over-year changes of +6.21% and +5.45%, respectively.
It is also important to note the recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there’s been a 1.3% fall in the Zacks Consensus EPS estimate. Right now, Boston Scientific possesses a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 12.92. This expresses a discount compared to the average Forward P/E of 19.58 of its industry.
Also, we should mention that BSX has a PEG ratio of 1.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. By the end of yesterday’s trading, the Medical – Products industry had an average PEG ratio of 1.72.
Source: finance.yahoo.com
